General
Preferred name
TICLOPIDINE
Synonyms
TICLOPIDINE HYDROCHLORIDE ()
53-32C ()
Ticlopidine HCl ()
Ticlodix ()
Ticlodone ()
Ticlopidine (hydrochloride) ()
PCR 5332 ()
Yuclid, Ticlopidinum, Ticlopidina,PCR 5332 ()
Ticlid ()
Tiklid ()
NSC-759165 ()
4-C-32 ()
Ipaton ()
Ticlopidin-puren ()
Ticlopidine-d4 (hydrochloride) ()
P&D ID
PD010172
CAS
55142-85-3
53885-35-1
2932627-17-1
Tags
prodrug
natural product
drug
available
Approved by
FDA
First approval
1991
Drug Status
approved
Drug indication
Inhibitor (platelet)
Stroke
Max Phase
Phase 4
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
INDICATION Used in patients, who have had a stroke or stroke precursors and who cannot take aspirin or aspirin has not worked, to try to prevent another thrombotic stroke.;
TOXICITY Single oral doses of ticlopidine at 1600 mg/kg and 500 mg/kg were lethal to rats and mice, respectively. Symptoms of acute toxicity were GI hemorrhage, convulsions, hypothermia, dyspnea, loss of equilibrium and abnormal gait. The FDA label includes a black-box warning of neutropenia, aplastic anemia, thrombotic thrombocytopenia purpura, and agranulocytosis, so it is necessary to monitor patients' WBC and platelets when they are taking ticlopidine.;
DESCRIPTION Ticlopidine is an antiplatelet drug. This compound is believed to be a prodrug, although the exact form of the active metabolite remains elusive. (GtoPdb)
Compound Sets
30
AdooQ Bioactive Compound Library
A11690
Cayman Chemical Bioactives
20770
33467
ChEMBL Approved Drugs
CHEMBL1717
CHEMBL833
ChEMBL Drugs
CHEMBL1717
CHEMBL833
Concise Guide to Pharmacology 2019/20
7307
Concise Guide to Pharmacology 2021/22
7307
Drug Repurposing Hub
DrugBank
DB00208
DrugBank Approved Drugs
DB00208
DrugCentral
2657
DrugCentral Approved Drugs
2657
DrugMAP
DMO946V
DrugMAP Approved Drugs
DMO946V
DrugMatrix
Enamine BioReference Compounds
EU-OPENSCREEN Bioactive Compound Library
EOS101656
Guide to Pharmacology
7307
Ki Database
Ticlopidine
LSP-MoA library (Laboratory of Systems Pharmacology)
CHEMBL833
Mcule NIBR MoA Box Subset
MCULE-3971692083
MedChem Express Bioactive Compound Library
HY-B0153A
HY-100386
NCATS Inxight Approved Drugs
OM90ZUW7M1
NIH Clinical Collections (NCC)
Novartis Chemogenetic Library (NIBR MoA Box)
NPC Screening Collection
Prestwick Chemical Library
ReFrame library
Selleckchem Bioactive Compound Library
ticlopidine-hydrochloride
ticlopidine
TargetMol Bioactive Compound Library
T0362
The Spectrum Collection
External IDs
63
Properties
(calculated by RDKit )
Molecular Weight
263.05
Hydrogen Bond Acceptors
2
Hydrogen Bond Donors
0
Rotatable Bonds
2
Ring Count
3
Aromatic Ring Count
2
cLogP
3.96
TPSA
3.24
Fraction CSP3
0.29
Chiral centers
0.0
Largest ring
6.0
QED
0.79
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Pathway
Neuroscience
Metabolic Enzyme/Protease
GPCR/G protein
Target
P2 Receptor
P2RY12
Cytochrome P450
Adenosine Receptor
Adenosine Receptor,P450 (e.g. CYP17)
Member status
member
MOA
P2Y12 (P2T) Antagonists
purinergic receptor antagonist
Indication
thrombosis, stroke
Disease Area
hematology, neurology/psychiatry
Therapeutic Class
Fibrinolytic Agents
Source data